The Role of Therapy Drug Using Rapamycin in Improvement of Multiple Sclerosis Patients: A Systematic Review

Multiple Sclerosis (MS) typically is classified as an autoimmune disease, which is affected by about one million people in the United States in 2018. MS disease damages the Myelin Neurons.The rapamycin molecules control the mammalian target of rapamycin (MTORS) of the immune system. In this review, the effects of the rapamycin drug on the treatment of MS patients is investigated by reviewing the published articles available in PubMed and google scholar database since 1999, after accepting rapamycin as a drug by Food and Drug Administration (FDA). By searching keywords Rapamycin, Multiple Sclerosis, Therapy in PubMed Total l49 articles were found that the title of 22 of themwas related to our purpose. 6 articles were chosen by reading the abstracts. The same process was done using the Google Scholar site. While 19800 results were found only 5 of them had related title, and among 3 of them having the related abstract article. All of the reviewarticles have mentioned minor side effects of the rapamycin such as a drop in blood sugar level, Skin cancer.It is mentioned in 3 articles that hypothesized MS inflammation and demyelination have decreased by using rapamycin. Another article is showed that the rapamycin suppresses the performance of T effector. Rapamycin reduces the level of IFN-y in the immune system. In addition, 2 articles have explained the repair of Myelin Neuron by rapamycin. The author of one the articles have examined biochemical and hematological parameters in MS Patients reported Minimum and maximum average volume platelet were lowered. Conclusions: Based onthe articles, the rapamycin has positive effects on the remedy of MS patients confirmed and it can be advised by the doctors.